Core Viewpoint - China Traditional Chinese Medicine (00570) is expected to report a net loss for the fiscal year ending December 31, 2025, with losses projected between RMB 350 million to 500 million, a significant decline from a net profit of RMB 20.77 million in the same period last year [1] Group 1: Financial Performance - The adjusted net profit for the current period is expected to decrease by 45% to 55%, compared to approximately RMB 635.5 million in the previous year [1] - The company’s stock price has dropped over 4%, currently trading at HKD 2.09, with a trading volume of HKD 11.2992 million [1] Group 2: Reasons for Loss - The transition from profit to loss is primarily attributed to the increased proportion of centralized procurement in the Chinese medicine formula granule business, leading to reduced revenue scale and profitability due to intensified market competition [1] - Additional factors contributing to the loss include increased impairment of goodwill, intangible assets, and credit impairment [1] - The adjusted net profit excludes impacts from goodwill and related asset group impairments, as well as tax payments made by certain subsidiaries [1]
中国中药跌超4% 预计2025年度盈转亏最多5亿元